In particular, resistance to EGFR inhibition in human glioma cells was attributed to compensatory signaling by IGF-IR (59), and insulin receptor/IGF-IR signaling was shown to confer resistance to Gefitinib in EGFR-dependent glioblastoma, through compensatory AKT activation (24). The gene discussed is EGFR; the disease is central nervous system cancer.